Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas

被引:24
作者
Arndt, D [1 ]
Zeisig, R [1 ]
Eue, I [1 ]
Sternberg, B [1 ]
Fichtner, I [1 ]
机构
[1] UNIV JENA,INST ULTRASTRUCT RES,D-6900 JENA,GERMANY
关键词
alkylphosphocholine; hexadecylphosphocholine; human breast carcinoma; sterically stabilized liposomes;
D O I
10.1023/A:1005798715192
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
New sterically stabilized liposomes derived from the antitumor agent hexadecylphosphocholine with reduced uptake by the mononuclear phagocyte system and improved antitumor activities were developed and tested. The bilayer of such sterically stabilized liposomes consists of hexadecylphosphocholine, cholesterol and polyethylene glycol-linked phosphoethanolamine. The measurement of carbon clearance in mice shows that these stabilized liposomes, in contrast to conventional alkylphosphocholine liposomes, are not largely engulfed by the mononuclear phagocyte system. Their therapeutic activity on experimental human breast carcinomas MaTu, MT-1 and MT-3 was tested in nude mice. Especially in the MaTu models the sterically stabilized hexadecylphosphocholine liposomes resulted in significantly reduced tumor growth in comparison to conventional hexadecylphosphocholine liposomes or free hexadecylphosphocholine. The enhanced therapeutic efficacy of sterically stabilized hexadecylphosphocholine liposomes is probably related to the extended circulation time of the formulation and its accumulation in tumors.
引用
收藏
页码:237 / 246
页数:10
相关论文
共 39 条
[1]   THE USE OF GLYCOLIPIDS AND HYDROPHILIC POLYMERS IN AVOIDING RAPID UPTAKE OF LIPOSOMES BY THE MONONUCLEAR PHAGOCYTE SYSTEM [J].
ALLEN, TM .
ADVANCED DRUG DELIVERY REVIEWS, 1994, 13 (03) :285-309
[2]  
ALLEN TM, 1992, CANCER RES, V52, P2431
[3]   LIPOSOMES WITH PROLONGED CIRCULATION TIMES - FACTORS AFFECTING UPTAKE BY RETICULOENDOTHELIAL AND OTHER TISSUES [J].
ALLEN, TM ;
HANSEN, C ;
RUTLEDGE, J .
BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 981 (01) :27-35
[4]   MEMBRANE-INTERACTIVE LIPIDS AS EXPERIMENTAL ANTICANCER DRUGS [J].
BERDEL, WE .
BRITISH JOURNAL OF CANCER, 1991, 64 (02) :208-211
[5]   THE INFLUENCE OF ALKYL-LYSOPHOSPHOLIPIDS AND LYSOPHOSPHOLIPID-ACTIVATED MACROPHAGES ON THE DEVELOPMENT OF METASTASIS OF 3-LEWIS LUNG-CARCINOMA [J].
BERDEL, WE ;
BAUSERT, WR ;
WELTZIEN, HU ;
MODOLELL, ML ;
WIDMANN, KH ;
MUNDER, PG .
EUROPEAN JOURNAL OF CANCER, 1980, 16 (09) :1199-1204
[6]  
BERGER MR, 1988, J CANC CLIN ONCOL, V114, P73
[7]   LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :91-97
[8]  
CLAVEL M, 1992, ANN ONCOL S1, V3, P65
[9]   HEXADECYLPHOSPHOCHOLINE - A NEW AND SELECTIVE ANTITUMOR DRUG [J].
EIBL, H ;
UNGER, C .
CANCER TREATMENT REVIEWS, 1990, 17 (2-3) :233-242
[10]  
FICHTNER I, 1992, In Vivo (Attiki), V6, P113